IGF-1 LR3 started life as an industrial reagent, not a drug. It is a recombinant analog of human insulin-like growth factor 1 (IGF-1), and most of the solid published work on it comes from biopharmaceutical cell-culture science, where it goes by names like Long R3 IGF-I or the trademarked LONG R3 IGF-I.
What it is
Native IGF-1 is a 70-amino-acid protein. IGF-1 LR3 is an 83-amino-acid version with two deliberate changes: an arginine swapped in for glutamic acid at position 3, and a 13-amino-acid extension added to the N-terminus. Those edits do something specific. They cut the molecule's affinity for IGF-binding proteins (IGFBPs) by more than 1000-fold, according to the Repligen product page. IGFBPs normally grab circulating IGF-1 and hold it back, so reducing that binding leaves more of the analog free to reach the IGF-1 receptor.
The practical result is a molecule that is more potent and more stable than either insulin or native IGF-1 in culture. Reference suppliers describe it as roughly 200 times more potent than insulin in supporting cell growth, and the Sigma-Aldrich datasheet and Repligen both list it as a supplement for serum-free or low-serum mammalian cell culture.
What the research actually shows
The published evidence is strongest in cell culture, which is what the compound was designed for. A 2006 study in Molecular Biotechnology by Voorhamme and Yandell tested it as an insulin alternative in serum-free systems. They reported that Long R3 IGF-I supported the growth and survival of Chinese hamster ovary (CHO) cells at concentrations at least 200-fold lower than insulin required, and that it activated IGF and insulin receptors more efficiently than native IGF-I in HEK293 cells (PubMed).
Mechanistically it works as an agonist at the IGF-1 receptor, a receptor tyrosine kinase, which sets off the downstream signaling that drives cell proliferation and survival. That part is well characterized.
What does not exist is a body of human clinical evidence. IGF-1 LR3 has no approved therapeutic use and carries no ATC drug classification. There are no published controlled trials in people establishing safety or benefit for any condition. Most of the muscle-and-recovery claims you will see attached to it online are extrapolations from IGF-1 biology and cell or animal work, not human trial data. Treat them as unproven.
Regulatory and anti-doping status
This matters for anyone weighing what the compound is. Exogenous IGF-1, including synthetic analogs, is on the World Anti-Doping Agency Prohibited List under peptide hormones and growth factors (class S2), and it is banned at all times, in and out of competition. The U.S. Anti-Doping Agency notes that pharmaceutical-grade IGF-1 is not widely available through legitimate channels and that exogenous IGF-1 should only ever be used when medically necessary and supervised by a physician (USADA). Anti-doping labs have also reported that long-chain IGF-1 (LR3 specifically) is already turning up in use, which is part of why detection methods for these analogs exist.
Material sold as IGF-1 LR3 to consumers is research-use-only and not approved for human consumption. None of this is medical or dosing advice.
The quality and testing angle
Because IGF-1 LR3 is a relatively large recombinant peptide, identity and purity are not trivial to confirm. The legitimate cell-culture supply chain (Repligen, Sigma-Aldrich and similar) sells it with lot-specific documentation and defined activity assays. The research-chemical market that sells it for unapproved uses generally does not operate to that standard. If you are evaluating a vendor, the things that actually tell you something are a recent, lot-matched certificate of analysis, an identity method appropriate for a protein this size (mass spec rather than HPLC alone), and a stated purity figure tied to that lot. peptideone aggregates third-party purity and identity testing where it exists; for a molecule like this, the gap between a real COA and a generic one is the whole story.